A little more than two years after announcing a $12.4 million round to finance early-stage efforts on its experimental therapy for Alzheimer's, Cambridge, MA-based NeuroPhage says it has landed $6.4 million from backers to work on pre-IND studies of the lead drug, NPT002.
Once drugs are approved, manufacturing is supposed to kick in and get the product out the door so drugmakers can start making some money. But recently, questions about manufacturing have not only been a stumbling block for some companies to getting approvals, they have broken up a relationship.
A new finding may shed more light on the role of inflammation in Parkinson's disease--a progressive degenerative disease marked by decreased levels of dopamine in the brain.
A little more than two years after signing up GlaxoSmithKline as its Big Pharma partner on an extended-release version of a carbidopa-levodopa combo for Parkinson's disease, Impax Laboratories is headed back to the bargaining table. The FDA rejected the drug based on manufacturing issues a few months ago, and a frustrated Glaxo has now decided to drop out of the game.
Alkermes spinout Civitas Therapeutics today reported positive topline results from a Phase II clinical trial of its Parkinson's drug CVT-301, which uses a respiratory delivery system to provide quick relief to patients experiencing motor fluctuations common to long-term treatment of the disease.
The body's ability to process fats has been connected to certain diseases like Alzheimer's and Parkinson's. Researchers have pinpointed an enzyme--ACOT7--in a mouse model that keeps the fats levels of neurons in the brain in check.
The common sweetener mannitol--already approved by the FDA as an intravenous diuretic--may also harbor properties that could help treat patients with Parkinson's disease.
Computer modeling has shed more light on the structure of a protein found clumped together in the neurons of those stricken with Parkinson's disease, opening a path that drug hunters could march down to find new ways of treating the neurological disease.
European scientists may have discovered the molecular processes involved in the early stages of Parkinson's disease--a clue that could be used to develop new treatments to counteract early Parkinson's cellular changes.
A month after it reported a decisive mid-stage trial failure for its Parkinson's therapy, the biotech says it has stopped spending money on R&D, plans to slash its head count and is looking to sell off its assets in ongoing talks with potential buyers.